These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32409608)

  • 1. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
    Drosu NC; Edelman ER; Housman DE
    Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
    Church TM; Verma D; Thompson J; Swaminathan S
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niclosamide inhibits lytic replication of Epstein-Barr virus by disrupting mTOR activation.
    Huang L; Yang M; Yuan Y; Li X; Kuang E
    Antiviral Res; 2017 Feb; 138():68-78. PubMed ID: 27939840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
    Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chidamide Induces Epstein-Barr Virus (EBV) Lytic Infection and Acts Synergistically with Tenofovir to Eliminate EBV-Positive Burkitt Lymphoma.
    Xu L; Zhang M; Tu D; Lu Z; Lu T; Ma D; Zhou Y; Zhang S; Ma Y; Yan D; Wang X; Sang W
    J Pharmacol Exp Ther; 2023 Dec; 387(3):288-298. PubMed ID: 37875309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.
    Callebaut C; Stepan G; Tian Y; Miller MD
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5909-16. PubMed ID: 26149992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
    Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
    J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication.
    Lyons DE; Yu KP; Vander Heiden JA; Heston L; Dittmer DP; El-Guindy A; Miller G
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
    Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
    Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.
    Whitehurst CB; Sanders MK; Law M; Wang FZ; Xiong J; Dittmer DP; Pagano JS
    J Virol; 2013 May; 87(9):5311-5. PubMed ID: 23449792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latent and lytic Epstein-Barr virus replication strategies.
    Tsurumi T; Fujita M; Kudoh A
    Rev Med Virol; 2005; 15(1):3-15. PubMed ID: 15386591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin Modification of the Epstein-Barr Virus Immediate Early Transactivator Zta.
    Zhao M; Nanbo A; Becnel D; Qin Z; Morris GF; Li L; Lin Z
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32847852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.
    Wang'ondu R; Teal S; Park R; Heston L; Delecluse H; Miller G
    PLoS One; 2015; 10(5):e0126088. PubMed ID: 25950714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uracil DNA glycosylase BKRF3 contributes to Epstein-Barr virus DNA replication through physical interactions with proteins in viral DNA replication complex.
    Su MT; Liu IH; Wu CW; Chang SM; Tsai CH; Yang PW; Chuang YC; Lee CP; Chen MR
    J Virol; 2014 Aug; 88(16):8883-99. PubMed ID: 24872582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.
    Dyson OF; Pagano JS; Whitehurst CB
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.
    Liu S; Li H; Chen L; Yang L; Li L; Tao Y; Li W; Li Z; Liu H; Tang M; Bode AM; Dong Z; Cao Y
    Carcinogenesis; 2013 Mar; 34(3):627-37. PubMed ID: 23180656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymerase theta is a synthetic lethal target for killing Epstein-Barr virus lymphomas.
    Willman GH; Xu H; Zeigler TM; McIntosh MT; Bhaduri-McIntosh S
    J Virol; 2024 Jul; 98(7):e0057224. PubMed ID: 38860782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
    Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
    Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
    Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
    Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.